Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
4,545actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-17 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-30 | actual | The whole study's end, after follow-up |
| First posted | 2026-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions
- Drug: Alirocumab
- Drug: Comparator: No PCSK9i Therapy (either mAb or siRNA)
Primary outcome
what the primary-completion date above is the date OFComposite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortality
measured From index up to 5 years follow up
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed